<DOC>
	<DOCNO>NCT00827606</DOCNO>
	<brief_summary>The purpose study characterize three year descriptive growth development ( ie , height , weight , body mass index , Tanner Stage ) efficacy cholesterol reduction pediatric subject Heterozygous Familial Hypercholesterolemia receive atorvastatin treatment .</brief_summary>
	<brief_title>Atorvastatin Three Year Pediatric Study</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Heterozygous familial hypercholesterolemia , age 615 , LDL great 4 mmol/l Active liver disease hepatic dysfunction , persistent elevation serum transaminase exceed three time upper limit normal ( ULN ) . Female childbearing potential use adequate contraceptive measure female pregnant breastfeeding . Any female becomes pregnant study participation immediately discontinue treatment counsel appropriately utero exposure . Known hypersensitivity HMGCoA reductase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pediatric heterozygous familial hypercholesterolemia</keyword>
</DOC>